Pluri Inc. PLUR

PLUR Company Overview

Pluri Inc. (NASDAQ: PLUR) is a biotechnology company focused on cell-based technologies and regenerative medicine. The company develops and manufactures placental expanded (PLX) cell therapies and related biologics for use in inflammatory, hematologic, radiation exposure, and regenerative medicine applications. Pluri operates within the biotechnology and advanced cell therapy industries, with activities spanning therapeutic development, contract manufacturing, and cell-based platform technologies.

The company’s primary business revolves around its proprietary three-dimensional cell expansion and manufacturing platform, which is designed to cultivate adherent stromal cells derived from human placentas. Its lead product candidates have historically targeted conditions involving hematopoietic recovery, inflammation, and tissue regeneration, including acute radiation syndrome and muscle injury indications. Pluri has also expanded into contract development and manufacturing services and collaborations involving cultivated cell technologies. Originally founded as Pluristem Therapeutics Inc., the company later rebranded to Pluri Inc. to reflect a broader strategy focused on multiple cell-based applications beyond traditional therapeutics.